

People

Appointments

GlaxoSmithKline appoint Reed Elsevier CEO to Board

Reed Elsevier Chief Executive Officer Crispin Davis has been appointed as a non-executive director at GlaxoSmithKline (<http://www.gsk.com>), effective from 1st July 2003. Davis joins two other new appointments to the Board, Lawrence Culp, President and CEO of Danaher Corp., and Sir Robert Wilson, Chairman of Rio Tinto. Davis will join the Remuneration Committee, and takes on his role in addition to his continuing CEO position at Reed Elsevier.

Sir Christopher Hogg, Chairman of GlaxoSmithKline, commented: 'I am delighted that Larry, Crispin and Sir Robert are joining the Board. They bring with them many years of experience and a track record of success in a variety of different industries. Their undoubted skills will further strengthen the Board'.

Davis joined Reed Elsevier as CEO in 1999. Before this, he was Chief Executive of Aegis Group plc, which he joined from Guinness plc, where he was Group Managing Director, United Distillers and a member of the main board of Guinness plc. Davis spent his early career with Procter & Gamble.

Aradigm announce executive appointments

Two appointments aimed at strengthening Aradigm (<http://www.aradigm.com>) in preparation for commercial manufacturing have been announced. V. Bryan Lawlis, Chief Operating Officer of Aradigm will add the title of President and in an expanded role will oversee the company's day-to-day operations and management. Bobba Venkatadri has been appointed as Senior Vice President of Operations, and will be responsible for leading the Operations team and preparing Aradigm's production facilities for US and international regulatory inspections toward commercialization of the company's needle-free drug delivery technologies. Richard Thompson, who previously held the title of President, will continue as Chief Executive Officer and Chairman of the Board.

Lawlis has served at Aradigm for a year and a half, and 'has shown tremendous

leadership' according to Thompson, who is 'very pleased to consolidate the daily operations of management in his capable hands'.

Venkatadri brings over 30 years of experience in pharmaceutical and biotechnological manufacturing to Aradigm. He has served as Executive Vice President of Operations for Diosynth RTP, a division of Akzo Nobel that manufactures recombinant proteins, as well as CEO of Molecular Biosystems, Executive Vice President of Centocor, President of Warner-Lambert Indonesia, and Vice President of Parke-Davis.

Two promotions at Covance

Covance (<http://www.covance.com>) has announced the promotion of Wendel Barr and Tony Cork as Co-Presidents in Lead Early Development, based in Madison, WI, USA and Harrogate, UK, respectively. Both Barr and Cork have also become Corporate Senior Vice Presidents and will serve on the Global Leadership Council of Covance.

Cork joined Covance in 2000 as Vice President and General Manager of Laboratories Europe. His 25-year career in the pharmaceutical industry has included management roles at Eli Lilly, Aventis and Schering-Plough, and has seen him work in six European countries and the Middle East.

Barr also joined Covance in 2000 as Vice President and General Manager of Laboratories, North America. Barr previously spent 15 years at GE Medical Systems before taking on the role of Global Vice President and General Manager of Marconi Medical Systems.

Joe Herring, President and COO of Covance, said: 'Both Wendel and Tony have grown into the role of President, demonstrating exceptional managerial and leadership attributes and have delivered spectacular results both in 2001 and 2002.'

Awards

Lexicon Genetics win IT award

Computerworld's 2003 21st Century Achievement Award for visionary use of information technology in medicine has been awarded to Lexicon Genetics (<http://www.lexgen.com>) for its innovative

Enterprise Resource Planning (ERP) System. Lexicon was nominated by Bob Dutkowsky, CEO of JD Edwards and was chosen from more than 400 nominations by a panel of distinguished judges.

The Computerworld Honors Program has existed for 15 years and recognizes the use of information technology in innovative ways to improve society.

Julia P. Gregory, Executive Vice President and Chief Financial Officer of Lexicon, said: 'We are honored to be the first genomics company to win this award for medicine and this is indicative of the importance of our work.'

Lexicon's ERP system was implemented to integrate the scientific, business and financial management processes necessary for the effective management of its Genome5000™ program. The program aims to discover the physiological functions and pharmaceutical use of 5000 genes over five years.

Young Investigator Award for Vascular Medicine

Qunsheng Dai, a research associate in the Division of Cardiology, Department of Medicine, Duke University Medical Center (<http://www.mc.duke.edu>), has been awarded the Young Investigator Award from the Society for Vascular Medicine and Biology. The award was given to Dai for his contributions to a study showing the effectiveness of using engineered zinc finger DNA-binding transcription factors (ZFP TFs) to increase vasculogenesis in ischaemic tissue, a joint investigation by Sangamo and Edwards Lifesciences Corporation.

Dai's work demonstrated that Sangamo and Edwards' lead therapeutic, a ZFP TF that activates the endogenous gene for vascular endothelial growth factor (VEGF), is able to increase the formation of new blood vessels, resulting in a significant increase in blood flow in the rabbit hind limb model of ischaemia.

The research was conducted at Brian Annex's laboratory at Duke University Medical Center. 'We are very proud of Qunsheng's success', commented Annex. Tyler Martin, Vice President of Development at Sangamo said: 'These data are part of our submission package for an IND application for peripheral vascular diseases. We congratulate Dr Dai on his award and wish him continued success.'

People was written by
Joanna Owens